This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,678.84, is a delivery order for the provision of XIFAXAN 550 mg tablets. The contract has an ultimate completion date of December 30, 2024 and is a firm fixed-price arrangement.
AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. This specific delivery order for XIFAXAN 550 mg tablets is likely a part of that broader IDC.
The contract award does not indicate any set-aside requirements, suggesting open competition. No subcontractors are mentioned in the information provided.
Generated 3/28/25, 9:49 AM